drugset / Trial / NCT01008917
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Phase 1
Completed
25 enrolled
University of California, San Francisco
Northwestern University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I study, which means that the goal is to see if the combination of Temsirolimus and Sorafenib is safe in patients with Hepatocellular Carcinoma. Sorafenib is a standard treatment for Hepatocellular Carcinoma. Temsirolimus is used to treat cancer in the kidneys. It is hoped that the addition of Temsirolimus will make Sorafenib more effective against Advanced Hepatocellular Carcinoma, however this can not be guaranteed. The addition of Temsirolimus to Sorafenib is not an FDA approved treatment for Advanced Hepatocellular cancer.
Timeline
- Start
- 2009-11-17
- Primary completion
- 2012-09-12
- Completion
- 2013-06-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | — | Oral |
| Subject | Temsirolimus | Small molecule | — | Intravenous |